Author

J. Aniscenko

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

S. L. Johnston· 3 shared A. Singanayagam· 2 shared L. J. Finney· 2 shared M. Calderazzo· 2 shared N. W. Bartlett· 2 shared P. Mallia· 2 shared A. A. M. Mohamed· 1 shared B. T. Kasdorf· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

S. L. Johnston

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Induction of neutralising antibodies against conserved rhinovirus capsid protein VP4 depends on presenting VP4 in a virus-like conformation

J. T. Kelly, G. K. Dellosa, J. Newman, R. Hills, A. A. M. Mohamed, J. Aniscenko, S. L. Johnston, T. J. Tuthill

This study shows that presenting VP4 peptides in a virus-like conformation induces neutralising antibodies in mice, highlighting the importance of antigenic conformation for vaccine design.

bioRxiv · Jun 28, 2024 · PreprintMicrobiology

Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon

L. J. Finney, N. Glanville, H. Farne, J. Aniscenko, P. Fenwick, S. Kemp, M.-B. Trujillo-Torralbo, M. Calderazzo, J. A. Wedzicha, P. Mallia, N. W. Bartlett, S. L. Johnston, A. Singanayagam

This study shows inhaled corticosteroids reduce ACE2 expression in COPD, potentially lowering SARS-CoV-2 susceptibility by suppressing type I interferon.

bioRxiv · Jun 13, 2020Immunology

MUC5AC drives COPD exacerbation severity through amplification of virus-induced airway inflammation

A. Singanayagam, J. Footitt, B. T. Kasdorf, M. Marczynski, M. T. Cross, L. J. Finney, M.-B. Trujillo Torralbo, M. Calderazzo, J. Zhu, J. Aniscenko, T. B. Clarke, P. L. Molyneaux, N. W. Bartlett, M. F. Moffatt, W. O. Cookson, , S. L. Johnston

This study identifies MUC5AC as a driver of COPD exacerbation severity by amplifying virus-induced airway inflammation through ATP release.

bioRxiv · Jul 22, 2019Immunology